Qlife: Testing is coming home - Redeye

Redeye initiates coverage of Qlife, which aims to bring clinical grade biomarker testing to the home setting thanks to its Egoo system. Qlife has already achieved sales of SEK77m of devices and tests for SARS-CoV-2, but it will now concentrate on CRP biomarker tests. We believe the technology may prove to be disruptive in the market.

Länk till analysen i sin helhet: https://www.redeye.se/research/869228/qlife-testing-is-coming-home?utm_source=finwire&utm_medium=RSS